Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

For the past three decades, apolipoprotein E (APOE) has been known as the single greatest
genetic modulator of sporadic Alzheimer disease (AD) risk, influencing both the average age …

Importance People with Down syndrome have a high risk of developing Alzheimer disease
dementia. However, penetrance and age at onset are considered variable, and the …

Down syndrome (DS) is caused by the triplication of chromosome 21 and is the most
common chromosomal disorder in humans. Those individuals with DS who live beyond age …

Background The diagnosis of symptomatic Alzheimer's disease is a clinical challenge in
adults with Down syndrome. Blood biomarkers would be of particular clinical importance in …

Adult individuals with Down syndrome (DS) develop Alzheimer disease (AD). Whether there
is a difference between AD in DS and AD regarding the structure of amyloid-β (Aβ) and tau …

The study of sex differences in Alzheimer's disease is increasingly recognized as a key
priority in research and clinical development. People with Down syndrome represent the …

Epidemiological evidence suggests that by the age of 40 years, all individuals with Down
syndrome (DS) have Alzheimer's disease (AD) neuropathology. Clinical diagnosis of …

Women are disproportionately affected by Alzheimer's disease (AD), yet little is known about
sex-specific effects on the development of AD in the Down syndrome (DS) population. DS is …

INTRODUCTION Almost all individuals with Down syndrome (DS) will develop
neuropathological features of Alzheimer's disease (AD). Understanding AD biomarker …